INCR · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$3.79-4.8%Nov 13 close
Figures through December 31, 2025, from the 20-F filed April 30, 2026
The quarter ending March 31, 2023, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2023 | 3 months toMar 31, 2022 | Change |
|---|---|---|---|
| Total Revenue | $33.1M | $27.2M | +21.72% |
| Profit | $28.7K | $168.2K | -82.96% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Intercure Ltd. has no earnings call transcript available.
(dba Canndoc) InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Intercure Ltd. filed on October 8, 2025 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.